PARP1 and neoplasm: Cells deficient in RAD51-mediated HDR through the inactivation of tumor suppressor genes like BRCA1 or BRCA2 exhibit hypersensitivity to poly-ADP ribose polymerase 1 (PARP1) inhibitors (Bryant et al., 2005; Farmer et al., 2005).